Recent progress of chemotherapy and biomarkers for gastroesophageal cancer

Osamu Maeda, Yuichi Ando

ORCID number: Osamu Maeda (0000-0003-4700-6541); Yuichi Ando (0000-0002-6849-2297).

Author contributions: Maeda O wrote the manuscript; Ando Y supervised the review; and all authors read and approved the final manuscript.

Conflict-of-interest statement: No potential conflict of interest.

Abstract

Key cytotoxic drugs of chemotherapy for gastroesophageal cancer include fluoropyrimidine, platinum, taxanes and irinotecan. Concurrent chemoradiotherapy is one of the main treatment strategies, especially for esophageal cancer. As molecular target agents, the anti-HER2 antibody trastuzumab for HER2-positive gastric cancer and the anti-angiogenesis agent ramucirumab combined with paclitaxel have been proven to improve the survival of gastric cancer patients. Recently, anti-PD-1 antibodies have become available as second- or later-line chemotherapy. PD-L1 expression and microsatellite instability are used to predict the effectiveness of immunotherapy. Furthermore, genome-wide analysis has improved our understanding of the biological features and molecular mechanisms of gastroesophageal cancer and will provide optimized treatment selection.

Key words: Gastroesophageal cancer; Chemotherapy; Biomarker; HER2

Core tip: This article reviewed the current status and recent developments of gastroesophageal cancer and its related biomarkers for treatment selection. Platinum, fluoropyrimidines, taxanes, irinotecan, trastuzumab and ramucirumab are key drugs. Recently, anti-PD-1 antibodies have become available. PD-L1 expression and microsatellite instability are used to predict the effectiveness of immunotherapy. Genome-wide analysis will provide a better understanding of the biology in gastroesophageal cancer.

Citation: Maeda O, Ando Y. Recent progress of chemotherapy and biomarkers for gastroesophageal cancer. World J Gastrointest Oncol 2019; 11(7): 518-526
INTRODUCTION

Gastroesophageal cancer is one of the main causes of death worldwide. According to a report by the World Health Organization, gastric cancer and esophageal cancer have the 3rd and 6th highest mortality rates, respectively. The best way to cure gastroesophageal cancer is the complete removal of cancer by surgical resection. Chemotherapy and radiation also contribute to improving the prognosis. Drugs used for systemic chemotherapy include cytotoxic agents and molecular target drugs. Recently, immune checkpoint inhibitors have also become available. Although multiple options can be used as a treatment strategy, the effectiveness and side effects are different depending on individual patients. Therefore, biomarkers to predict the effectiveness for the optimization of treatment selection and individualization are desired. In the present review, current chemotherapy options for gastroesophageal cancer and biomarkers are discussed.

FIRST-LINE CHEMOTHERAPY FOR GASTRIC CANCER

**Doublet regimens for gastric cancer**

As first-line chemotherapy for gastroesophageal cancer, a combination of platinum and fluoropyrimidine is essential. Doublet or triplet platinum/fluoropyrimidine combinations are recommended for fit patients with advanced gastric cancer\(^4\). Since oral fluoropyrimidines have the advantage of simplicity, many studies using S-1 or capecitabine have been performed. In the SPIRITS trial, the combination of oral fluoropyrimidine S-1 and cisplatin (SP) improved the survival of advanced gastric cancer patients compared with S-1 alone (median survival time: 13.0 mo vs 11.0 mo, \(P = 0.04\)\(^2\)). Fluorouracil, leucovorin plus oxaliplatin or cisplatin\(^3\) was also effective. The combination of another oral fluoropyrimidine, capecitabine, with cisplatin showed significant noninferiority for progression-free survival vs fluorouracil plus cisplatin (FP)\(^4\). Cisplatin induces severe nausea and vomiting, \textit{i.e.}, it is highly emetogenic, and it also has strong nephrotoxicity, in which a large amount infusion is necessary to prevent renal impairment. In contrast, oxaliplatin is moderately emetogenic and less nephrotoxic than cisplatin. A study comparing two platinum and two fluoropyrimidine drugs showed that capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin\(^5\). For oral fluoropyrimidine, the equality of S-1 and capecitabine in effectiveness was evaluated. A comparison between S-1 plus oxaliplatin and capecitabine plus oxaliplatin\(^6\) showed equal efficacy. In a comparison with S-1 plus cisplatin and S-1 plus oxaliplatin (SOX) (G-SOX trial), both showed equivalent efficacy\(^7\). According to a meta-analysis comparing fluoropyrimidines, toxicity profiles were different, but a lower frequency of relevant adverse events was observed with S-1. This report concluded that choosing fluoropyrimidines should be based on their individual toxicity profiles because their efficacies was similar\(^8\).

**Triplet regimens for gastric cancer**

To strengthen the efficacy of first-line chemotherapy, triplet regimens including fluorouracil, platinum and taxane have been investigated. In the V325 study, combination with docetaxel, cisplatin and fluorouracil was superior in survival compared with FP\(^9,10\) (median survival time: 9.2 mo vs 8.6 mo, \(P = 0.02\)). However, severe adverse events, including grade 3 or 4 neutropenia and complicated neutropenia, were observed in 82% and 29% of the patients, respectively. In triplet regimens, capecitabine and S-1 were also used as fluoropyrimidines, and oxaliplatin was used as platinum. The combination of docetaxel, cisplatin and capecitabine (DCX)\(^11\) for advanced cancer achieved a median overall survival of 14.4 mo, but 62.5% of patients experienced grade 3 or 4 neutropenia. DCX was reported to be used as neoadjuvant chemotherapy, which was administered before surgery for resectable diseases\(^12\), and 63% of the patients achieved R0 resection. To maintain effectiveness and avoid severe adverse events, a modified DCX regimen in which docetaxel was reduced was reported\(^13\). With this regimen, three out of eight patients underwent conversion gastrectomy and achieved long-term survival.
The combination with docetaxel, cisplatin and S-1 for unresectable gastric cancer (KDOG 0601) was also reported[14]. In this study, the objective response rate was 81%, and the median survival time was 18.5 mo. In a study with docetaxel, cisplatin and S-1 (DCS) as neoadjuvant chemotherapy (JCOG1002), the response rate was 57.7%, and R0 resection was achieved in 84.6% of patients[15]. In another study (JCOG1002), neoadjuvant DCS achieved a 90% R0 resection rate[16].

**HER2-positive gastric cancer**

Approximately 20% of gastric cancer is HER2 positive, and the anti-HER2 antibody trastuzumab is effective. In comparison between combination cisplatin plus capecitabine with or without trastuzumab (ToGA trial), the median overall survival was 13.8 mo with trastuzumab and 11.1 mo without trastuzumab[17]. For HER2-positive breast cancer, lapatinib, trastuzumab emtansine and pertuzumab are available as anti-HER2 agents. However, for HER2-positive gastric cancer, the trials of lapatinib[18-19], trastuzumab emtansine (T-DM1)[20] and pertuzumab[21] did not show a survival benefit and were not used for gastric cancer. Therefore, only trastuzumab as an anti-HER2 agent is available for HER2-positive gastric cancer.

**SECOND OR LATER-LINE FOR GASTRIC CANCER**

Several phase III trials revealed evidence of a survival benefit in second-line chemotherapy. For example, the COUGAR-02[22] trial showed the benefit of docetaxel, an improvement of survival with irinotecan[23] was proven by Arbeitsgemeinschaft Internistische Onkologie, and a Korean study revealed the effectiveness of docetaxel or irinotecan[24]. The WJOG 4007 study compared paclitaxel and irinotecan and showed an equivalent effectiveness of both agents[25]. Ramucirumab is a molecular target agent that binds to vascular endothelial growth factor receptor-2 (VEGFR2) and inhibits VEGFR-mediated angiogenesis. In the REGARD trial, ramucirumab monotherapy showed a longer survival rate compared with the placebo[26]. The RAINBOW trial revealed the benefit of the addition of ramucirumab to paclitaxel[27]. Apatinib is a tyrosine kinase inhibitor that selectively binds to and strongly inhibits VEGFR-2, with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Apatinib significantly improved the survival of patients for whom two or more prior lines of chemotherapy had failed[28].

Trifluridine/tipiracil (TAS-102) is a cytotoxic chemotherapy consisting of a thymidine-based nucleoside analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil. Trifluridine is incorporated into DNA, resulting in DNA dysfunction, and tipiracil blocks trifluridine degradation by thymidine phosphorylase, increasing trifluridine bioavailability. Trifluridine/tipiracil improved the overall survival compared with the placebo in patients who had previously received two or more regimens[29]. Recently, the effectiveness of immune checkpoint inhibitors has been shown in various cancers. Nivolumab is an anti-PD-1 antibody, and its survival benefit was proven as a third or later-line chemotherapy[30]. Pembrolizumab is also an anti-PD-1 antibody and demonstrated promising activity and manageable safety in patients with advanced gastric or gastroesophageal junction cancer who had previously received at least 2 lines of treatment[31]. In this study, durable responses were observed in patients with PD-L1-positive and PD-L1-negative tumors. In another study, second-line therapy with pembrolizumab and paclitaxel was compared for gastric cancer with a combined positive score (CPS) of 1 or higher of PD-L1. CPS is defined as the number of PD-L1-positive cells (tumor cells, lymphocytes, macrophages) as a proportion of the total number of tumor cells multiplied by 100. Although pembrolizumab did not significantly improve overall survival compared with paclitaxel as a second-line therapy for advanced gastric or gastroesophageal junction cancer, pembrolizumab had a better safety profile than paclitaxel[32].

**CHEMOTHERAPY AND CONCURRENT CHEMORADIOThERAPY FOR ESOPHAGEAL CANCER**

For esophageal cancer, fluoropyrimidines and platinum are essential, and in addition to taxanes, they are also useful in gastric cancer. Perioperative FP was evaluated for gastroesophageal adenocarcinoma, and superiority in overall survival was shown compared with surgery alone[33]. For squamous cell carcinoma, surgery following adjuvant FP was proven to be superior to surgery alone (JCOG9204)[34]. In comparison
between preoperative and postoperative FP for localized advanced squamous cell carcinoma of the esophagus, preoperative FP was superior to postoperative FP (JCOG9907)\[49].

**Chemoradiotherapy for esophageal cancer**

Chemoradiation with FP followed by surgery (CALGB 9781) showed superiority compared with surgery alone\[48]. In the FFCD 9102 trial, no benefit was shown for the addition of surgery after chemoradiation with FP compared with the continuation of additional chemoradiation for squamous cell carcinoma in the esophagus\[47]. Preoperative chemoradiotherapy with a combination of carboplatin and paclitaxel was superior to surgery alone\[46]. For esophageal adenocarcinoma, squamous cell, or adenosquamous carcinoma, a comparison with FP and the combination of oxaliplatin, leucovorin and fluorouracil revealed that both regimens are effective as definitive chemoradiotherapy for patients unsuitable for surgery\[45,48]. For stage II-III esophageal squamous cell carcinoma, definitive chemoradiation with FP was effective. The median survival time was 29 mo, with 3- and 5-year survival rates of 44.7% and 36.8%, respectively, which was comparable to surgery with adjuvant chemotherapy (JCOG9906)\[48]. For stage I esophageal squamous cell carcinoma, chemoradiation with FP achieved 80.5% of the four-year survival proportion and 68% of the 4-year major relapse-free survival (JCOG9708)\[48]. For patients with advanced squamous cell carcinoma of the thoracic esophagus having either T4 tumor or distant lymph node metastasis (M1 Lym), chemoradiation with FP was administered. The response rate was 68.3%, the complete response was 15%, the median survival time was 305.5 days, and the 2-year survival rate was 31.5% (JCOG 9516)\[49]. The optimal dose of radiation was also studied. For definitive chemoradiotherapy using FP, the INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial compared 64.8 Gy and 50.4 Gy\[50]. The higher radiation dose did not increase survival or local/regional control, and they concluded that the standard radiation dose for patients treated with concurrent 5-FU and cisplatin chemotherapy is 50.4 Gy\[50].

**Taxanes for esophageal cancer**

As for second-line chemotherapy, taxanes are often used. In a phase II trial using docetaxel in which the majority of patients had squamous cell carcinoma, the response rate was 20%, and the median survival time was 8.1 mo\[45]. In the COUGAR-02 trial, docetaxel was effective for esophageal adenocarcinoma as well as gastric adenocarcinoma\[51]. Paclitaxel was also effective. In a phase II trial for esophageal cancer mainly of squamous cell carcinoma, the response rate was 44.2%, and the median survival time was 10.4 mo\[52]. In another trial with the majority of patients in which the histological diagnosis was adenocarcinoma, paclitaxel was also effective\[52].

**Other molecular targeted agents**

As described above, the angiogenesis inhibitor ramucirumab and the anti-HER2 antibody trastuzumab are effective for gastric cancer. Although other molecular targeted agents were investigated in multiple clinical trials, the benefits of most of them have not been proven. Bevacizumab is an angiogenesis inhibitor that is widely used for cancer, including colorectal cancer and lung cancer. For gastric cancer, bevacizumab was examined combined with cytotoxic chemotherapy, and the survival benefit was not proven (AVAGAST trial)\[53]. An anti-EGFR antibody, panitumumab, for first-line chemotherapy did not improve survival\[54]. The EGFR inhibitor erlotinib is active in patients with gastroesophageal adenocarcinomas but appears inactive in gastric cancers (SWOG 0127)\[55]. The anti-EGFR antibody cetuximab is useful for head and neck cancers and colorectal cancer with the wild-type RAS gene. A trial of cetuximab for gastric cancer evaluated the effect of the addition to capecitabine and cisplatin (EXPAND). They concluded that the addition of cetuximab to capecitabine-cisplatin provided no additional benefit to chemotherapy alone\[56]. In the CALGB 80403 (Alliance)/E1206 trial, cetuximab was applied for esophageal cancer with multiple regimens\[57]. However, a trial of chemoradiotherapy with cetuximab in patients with esophageal cancer (SCOPE1) showed a shortened survival time compared with chemoradiotherapy without cetuximab. Therefore, concurrent chemoradiotherapy with cetuximab is not recommended\[58]. Another anti-EGFR antibody, panitumumab, was also evaluated for esophagogastric cancer (REAL3)\[59]. The addition of panitumumab does not increase overall survival and cannot be recommended.

**Microsatellite instability**

DNA mismatch repair (MMR) is a mechanism for recognizing and repairing DNA replication errors. Microsatellite Instability (MSI) is the condition of having a predisposition to mutations that result from deficient MMR. A potential determinant
of the response to immune checkpoint inhibitors is mutation-associated neoantigens (MANAs) that are encoded by cancers. MMR-deficient cancers are predicted to have many MANAs that might be recognized by the immune system. The effect of pembrolizumab on patients with advanced MMR-deficient cancers across 12 different tumor types was evaluated.[58] Responses were durable, objective responses were observed in 53% of patients, and complete responses were achieved in 21% of patients. According to another report, the response of pembrolizumab for MMR–deficient colorectal cancers is much better than that for MMR-proficient colorectal cancers. Furthermore, patients with MMR–deficient colorectal cancer had responses similar to those of patients with MMR-deficient colorectal cancer.[54]. Therefore, MSI/MMR deficiency is useful as a biomarker to predict the effectiveness of immunotherapy for solid tumors, including gastroesophageal cancer.

**CURRENT APPLICATION OF BIOMARKERS AND FUTURE PERSPECTIVES**

As mentioned above, HER2 overexpression and amplification are applied to define the indication of trastuzumab. The expression of PD-L1 might be useful in predicting the effect of pembrolizumab in some situations. MSI is also useful for selecting patients who are suitable to use pembrolizumab for gastroesophageal cancer as well as other solid tumors.

The Cancer Genome Atlas (TCGA) project proposes a molecular classification dividing gastric cancer into four subtypes:[59] Tumors positive for Epstein–Barr virus, which display PIK3CA mutations, DNA hypermethylation, and an amplification of JAK2, PD-L1 and PD-L2; microsatellite unstable tumors, which show elevated mutation rates; genomically stable tumors, which are enriched for the diffuse histological variant and mutations of RhoA or fusions involving RHO-family GTPase-activating proteins; and tumors with chromosomal instability, which show aneuploidy and the focal amplification of receptor tyrosine kinases. TCGA also showed the biological features of esophageal cancer.[60]. According to this information, esophageal squamous cell carcinomas resembled squamous carcinomas of other organs more than they did esophageal adenocarcinomas. In contrast, esophageal adenocarcinomas strongly resembled the chromosomally unstable variant of gastric adenocarcinoma, suggesting that these cancers could be considered a single disease entity.

A study of perioperative chemotherapy for gastric cancer extracted the expression of seven genes (CDH1, ELOVL5, EGFR, PI3K1B, FGF1, CDA4v8.10 and TBCE) as biomarkers to predict the prognosis of the patient.[56]. In another study, the DNA methylation profile was potentially related to a resistance to chemotherapy for gastric cancer.[57]. The exploration of new antitumor agents accompanied by the development of a molecular diagnosis will optimize the selection of therapy for individual patients.

**REFERENCES**

1. **Smyth EC**, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2016; 27: v33-v49 [PMID: 27064260 DOI: 10.1093/annonc/mdw350]

2. **Koizumi W**, Narahara H, Hara T, Takagane A, Akita T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takayama W, Toh Y, Nagata T, Takagi S, Yamamura Y, Yamaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. *Lancet Oncol* 2008; 9: 215-221 [PMID: 18282805 DOI: 10.1016/S1470-2045(08)70055-4]

3. **Al-Batran SE**, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rehwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Attma A, Bokemeier C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastric adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26: 1435-1442 [PMID: 18409393 DOI: 10.1200/jco.2007.13.9378]

4. **Kang YK**, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinietser M, Guan Z, Khasanov R, Zheng L, Philico-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line treatment in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Ann Oncol* 2009; 20: 666-673 [PMID: 19151211 DOI: 10.1093/annonc/mdn127]

5. **Cunningham D**, Starling N, Rao S, Iverson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Cunningham D, Pauligk C, Attma R, Bokemeier C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2008; 19:v33-v49 [PMID: 18409393 DOI: 10.1200/jco.2007.13.9378]

6. **Kim GM**, Jeung HC, Rha SY, Kim HS, Jung I, Nam BH, Lee KH, Chung HC. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer* 2012; 48: 518-526 [PMID: 22443774 DOI: 10.1016/j.ejca.2011.12.017]
Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sagimoto N, Nishima T, Amagai K, Chin K, Niwa Y, Tsuji A, Inamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hirooka S, Shimada K, Miwa H, Hamada C, Hyodo I. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. *Ann Oncol* 2015; 26: 141-148 [PMID: 25316259 DOI: 10.1093/annonc/mdu472]

Ter Veer E, Ngai LL, Valkenhorf GV, Mohammad NH, Anderegg MCJ, van Oijen MGH, van Laarhoven HWM. Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophageal cancer: A network meta-analysis. *Sci Rep* 2017; 7: 7142 [PMID: 28769123 DOI: 10.1038/s41598-017-07750-y]

Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E; V-325 Study Group. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. *J Clin Oncol* 2007; 25: 3205-3209 [PMID: 17664467 DOI: 10.1200/JCO.2006.10.4968]

Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 2006; 24: 4991-4997 [PMID: 17075117 DOI: 10.1200/JCO.2006.06.8429]

Kang YK, Ryu MH, Yoo C, Chang HM, Yook JH, Oh ST, Kim BS, Kim TW. Phase II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. *Cancer Chemother Pharmacol* 2011; 67: 1435-1443 [PMID: 20811894 DOI: 10.1007/s00280-010-1444-4]

Sym SJ, Chang HM, Ryu MH, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK. Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. *Ann Surg Oncol* 2010; 17: 1024-1032 [PMID: 19941081 DOI: 10.1245/s10434-009-0836-1]

Maeda O, Matsuoka A, Miyahara R, Funasaka K, Hirooka Y, Fukaya M, Nagino M, Kodera Y, Goto H, Ando Y. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. *World J Gastroenterol* 2017; 23: 1090-1097 [PMID: 28246483 DOI: 10.3748/wjg.v23.i6.1090]

Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, Takagi S, Azuma M, Azuma M, Abe T, Ishido K, Nakatani K, Naruke A, Kikuta C. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). *Cancer Chemother Pharmacol* 2012; 69: 407-413 [PMID: 21796483 DOI: 10.1007/s00280-011-1701-1]

Ito S, Sano T, Mizusawa J, Takahara D, Katayama H, Katai H, Kawashima Y, Kinoshita T, Terashima M, Nasamono A, Nakamoto M, Ono H, Sasako M, A phase II study of preoperative chemotherapy with docetaxel, cisplatin and S-1 followed by gastroctomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. *Gastric Cancer* 2017; 20: 322-331 [PMID: 27299887 DOI: 10.1007/s10120-016-0164-2]

Hosoda K, Azuma M, Katada C, Moriya H, Mieno H, Iishido K, Ern A, Ushiku H, Wada T, Washio M, Watanabe A, Higuchi K, Tanabe S, Kikumed W, Watanabe M, Yamashita K. A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial. *Gastric Cancer* 2019; 22: 598-606 [PMID: 30284080 DOI: 10.1007/s10120-018-0884-0]

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sandwai K, Lordick F, Ohtsu A, Oumuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Leible M, Rischoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; 376: 687-697 [PMID: 20728230 DOI: 10.1016/S0140-6736(10)61121-X]

Hecht JR, Bang YJ, Qin SK, Chung HC, Xu XM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, Van Cutsem E, Aprile G, Kulikov E, Hill J, Leible M, Rischoff J, Kang YK. Feasibility study. *J Clin Oncol* 2016; 34: 443-451 [PMID: 26628478 DOI: 10.1200/JCO.2015.62.6598]

Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu XM, Tsuji A, Oumuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A, Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study of the JCOG2009 trial. *Ann Oncol* 2014; 32: 2039-2049 [PMID: 24868024 DOI: 10.1093/annonc/mdu472]

Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shiota K, Phillips GD, van der Has J, Harle-Yege ML, Althaus BH, Kang YK. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. *Lancet Oncol* 2017; 18: 640-653 [PMID: 28343975 DOI: 10.1016/S1470-2045(17)31111-0]

Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K, Kang YK. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. *Lancet Oncol* 2018; 19: 1372-1384 [PMID: 30217672 DOI: 10.1016/S1470-2045(18)30481-9]

Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyde L, Madhussur S, Middleton GW, Swinson D, Fulk S, Chau I, Cunningham D, Karacas C, Cook N, Blazey JM, Dunn JA; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophageal gastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncol* 2014; 15: 78-86 [PMID: 24332328 DOI: 10.1016/S1470-2045(13)70549-7]

Thuss-Patience PC, Kretzschmar A, Bichev D, Deis T, Hinke A, Breithaupt K, Degen Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for trastuzumab versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische
Onkologie (AJO). Eur J Cancer 2011; 47: 2306-2314 [PMID: 21742485 DOI: 10.1016/j.ejca.2011.06.002]

Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care alone. J Clin Oncol 2012; 30: 1513-1518 [PMID: 22412140 DOI: 10.1200/JCO.2011.39.4585]

Hironaka S, Ueda S, Yasaki H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimohaira H, Tokunaga S, Moriwaki T, Etaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boka N, Hyodo I. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer with severe peritoneal metastatic disease with failure of prior chemotherapy plus fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 2013; 31: 4438-4444 [PMID: 24190112 DOI: 10.1200/JCO.2012.48.5805]

Fuchs CS, Tomasek J, Yong CJ, Dimmitu F, Passalaqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melibar B, Tehile M, Topnuaz E, Zelberg JR, Chau I, Campbell W, Sivanandan C, Pikoulis K, Kostoumalis T, Hsu Y, Liepa AM, Gao L, Schigote T, Tabernero J. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39 [PMID: 24094768 DOI: 10.1016/S0140-6736(13)61515-5]

Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajanji I, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-1235 [PMID: 25240822 DOI: 10.1016/S1470-2045(14)04326-6]

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu Y, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Bi J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu J, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol 2016; 34: 1448-1454 [PMID: 26884585 DOI: 10.1200/JCO.2015.63.5995]

Shitara K, Doi T, Dvorkin M, Mansoor W, Arakura HT, Prokharau A, Alisma G, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yaluč S, Fujitani K, Beretta GD, Van Cutsem E, Winkler RE, Makris K, Ison DH, Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavilypretreated metastatic gastric cancer (TAGES): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2018; 19: 1437-1448 [PMID: 30355453 DOI: 10.1016/S1470-2045(18)30739-3]

Kang YK, Boka N, Satoh T, Ryu MH, Chao Y, Kato C, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee K, Hamamoto Y, Kim JH, Chiu K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4536-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390: 2461-2471 [PMID: 28939052 DOI: 10.1016/S0140-6736(17)31827-5]

Fuchs CS, Doi T, Jiang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catalano OA, Gressler VD, Oh SC, Scherf H, Varga R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrozulimab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018; 4: e1800013 [PMID: 29545932 DOI: 10.1001/jamaoncol.2018.0013]

Shitara K, OzgiroyluM, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Eekhout E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, placebo-controlled, phase 3 trial. Lancet 2018; 392: 123-133 [PMID: 29880231 DOI: 10.1016/S0140-6736(18)31257-1]

Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for stage IIIA and IIB gastric or gastro-oesophageal junction cancer: a phase 3, randomised, controlled trial. Lancet Oncol 2013; 14: 1513-1518 [PMID: 22412140 DOI: 10.1016/S1470-2045(13)60353-6]

Ando N, Iruka T, Ide H, Ishida K, Shinoda M, Nishimaki T, Takiyama W, Watanabe H, Isono K, Aoyama N, MAKUUCHI T, Tanaka O, Yamana H, Ikueshi K, Saito T, Iwasaki M, Fukuda Y, Kato H, Yoshikawa T, Oh SC, Bai LY, Tamura T, Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Kudoh S, Watanabe M, Kudoh S, Kudo S, Okumura N, Kurokawa K, Ueno N, Ogino K, Shitara K, Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Wilke H; REGARD Trial Investigators.仑氟定/替匹拉西单药治疗既往治疗失败的胃癌或胃食管结合部癌的随机对照试验(ONO-4538-19): 一项国际性、多中心、随机对照、安慰剂对照的3期试验. Lancet Oncol 2018; 19: 68-74 [PMID: 28179260 DOI: 10.1016/S1470-2045(18)30499-9]

Maeda O et al. Chemotherapy and biomarkers for gastroesophageal cancer
Martel-Lafay I, Michel P, Lalcer-Moscado C, François E, Créhange G, Abdelghani MB, Juzyba N, Bedene L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiation with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE/ACCORD17): final results of a randomised, phase 3/2 trial. Lancet Oncol 2014; 15: 305-314 [PMID: 24556041 DOI: 10.1016/S1470-2045(14)00282-2]

Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, Takihara K, Komatsu Y, Miyata Y, Fukuda H; Gastrointestinal Oncology Study Group of the Japanese Clinical Oncology Group (JCOG). Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG9906). Int J Radiat Oncol Biol Phys 2011; 81: 684-690 [PMID: 20922685 DOI: 10.1016/j.ijrobp.2010.06.033]

Kato H, Sato A, Fukuda H, Kagami Y, Udagawa H, Togo A, Ando N, Tanaka O, Shinoda M, Yamana H, Ishikura S. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol 2009; 39: 638-643 [PMID: 19549720 DOI: 10.1093/jjco/hyp899]

Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group (JEGO)/Japanese Clinical Oncology Group Trial (JCOG9516). Jpn J Clin Oncol 2004; 34: 615-619 [PMID: 15591460 DOI: 10.1093/jjco/hyh107]

Minsky BD, Pajak TF, Ginsburg RJ, Pisanskys TM, Martensson J, Komaki R, Okawara G, Rosenthal SA, Selsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174 [PMID: 11871057 DOI: 10.1200/JCO.2002.20.5.1167]

Muro K, Hamasugii T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takayama W, Ohtsu T. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004; 15: 955-959 [PMID: 15151954 DOI: 10.1093/annonc/mdh231]

Kato K, Tarih M, Hiroaka S, Muro K, Takihara K, Hamamoto Y, Imamura H, Amano N, Seriu T. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 2011; 67: 1265-1272 [PMID: 20703479 DOI: 10.1007/s00280-010-1422-x]

Ison DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007; 18: 898-902 [PMID: 17531256 DOI: 10.1093/annonc/mdm004]

Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawai A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Stanssens M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-3976 [PMID: 21844504 DOI: 10.1200/JCO.2011.36.2236]

Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wolterspoon A, Saffery C, Middleton G, Wadley J, Ferry D, Mansoor W, Coxon S, Hyder I,真人 S, Slater S, Peckitt C, Barbachano Y. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophaogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 481-489 [PMID: 23594787 DOI: 10.1016/S1470-2045(13)70966-4]

Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blankie CD, Abbruzzese J. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24: 4922-4927 [PMID: 17050878 DOI: 10.1200/JCO.2006.07.1316]

Lordick F, Kang YK, Chung HC, Salaman P, Oh SC, Boku N, Kurokawa T, Goto N, Boku N, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with or without cetuximab in patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 490-499 [PMID: 23594786 DOI: 10.1016/S1470-2045(13)70102-5]

Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ison DH, Villalflor VM, Cohen SJ, Mayer RJ, Vennok A, Benson AB, Goldberg RM. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol 2016; 34: 2736-2742 [PMID: 27382909 DOI: 10.1200/JCO.2015.65.5092]

Crosby T, Hunt CN, Falk S, Colliers S, Mackenzie S, Staffurths J, Bevan M, Llacer-Moscardo C, french E, Créhange G, Abdelghani MB, Juzyna B, Martel-Lafay I, Michel P, Lalcer-Moscado C, Waddell T, Cunningham D, Blazey J, Roy R, Maughan T, Griffiths G. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 2013; 14: 627-637 [PMID: 23623280 DOI: 10.1016/S1470-2045(13)70136-0]

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aullakh LK, Lu S, Kemberling H, Waddell T, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zeahe A, Fisher GA, Crocenzi TS, Lee JH, Green TE, Caffrey FG, Ciombor KK, Earying AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Copel L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader A, Taube J, Hausse F, Spoelz D, Xiao N, Pardoll DM, papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409-413 [PMID: 28596306 DOI: 10.1126/science.aam0733]

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Earying AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zeahe A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Blajiee F, Huenr J, Hrbuan RH, Wood LD, Cuka N, Pardoll D, Papadopoulos N, Kizner KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372: 540-5250 [PMID: 26028255 DOI: 10.1056/NEJMoa1500596]

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209 [PMID: 25079317 DOI: 10.1038/nature13480]

Cancer Genome Atlas Research Network. Analysis Working Group: Asian University; BC Cancer Agency; Brigham and Women’s Hospital; Broad Institute; Brown University; Case Western Reserve University; Dana-Farber Cancer Institute; Duke University; Greater Poland Cancer Centre; Harvard Medical School; Institute for Systems Biology; KU Leuven; Mayo Clinic; Memorial Sloan Kettering Cancer Center; National Cancer Institute; Nationwide Children’s Hospital; Stanford University; University of Alabama; University of Michigan; University of North Carolina; University of Pittsburgh; University of Rochester; University of Southern California; University of Texas MD Anderson Cancer Center;
University of Washington; Van Andel Research Institute; Vanderbilt University; Washington University; Genome Sequencing Center: Broad Institute; Washington University in St. Louis; Genome Characterization Centers: BC Cancer Agency; Broad Institute; Harvard Medical School; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; University of North Carolina; University of Southern California Epigenome Center; University of Texas MD Anderson Cancer Center; Van Andel Research Institute; Genome Data Analysis Centers: Broad Institute; Brown University.; Harvard Medical School; Institute for Systems Biology; Memorial Sloan Kettering Cancer Center; University of California Santa Cruz; University of Texas MD Anderson Cancer Center; Biospecimen Core Resource: International Genomics Consortium; Research Institute at Nationwide Children’s Hospital; Tissue Source Sites: Analytic Biologic Services; Asan Medical Center, Asterand Bioscience; Barretos Cancer Hospital; BioreclamationIVT; Botkin Municipal Clinic; Chonnam National University Medical School; Christiana Care Health System; Cureline; Duke University; Emory University; Erasmus University; Indiana University School of Medicine; Institute of Oncology of Moldova; International Genomics Consortium; Invidimed, Israeiltisches Krankenhaus Hamburg; Keimyung University School of Medicine; Memorial Sloan Kettering Cancer Center; National Cancer Center Goyang; Ontario Tumour Bank; Peter MacCallum Cancer Centre; Pusan National University Medical School; Ribeirão Preto Medical School; St. Joseph’s Hospital &Medical Center; St. Petersburg Academic University; Tayside Tissue Bank; University of Dundee; University of Kansas Medical Center; University of Michigan; University of North Carolina at Chapel Hill; University of Pittsburgh School of Medicine; University of Texas MD Anderson Cancer Center; Disease Working Group: Duke University; Memorial Sloan Kettering Cancer Center; National Cancer Institute; University of Texas MD Anderson Cancer Center; Yonsei University College of Medicine; Data Coordination Center: CSRA Inc; Project Team: National Institutes of Health. Integrated genomic characterization of oesophageal carcinoma. Nature 2017; 541: 169-175 [PMID: 28052061 DOI: 10.1038/nature20805]

Smyth EC, Nyamundanda G, Cunningham D, Fontana E, Ragulan C, Tan IB, Lin SJ, Wotherspoon A, Nankivell M, Fassan M, Lampis A, Hahne JC, Davies AR, Lagergren J, Gossage JA, Maisey N, Green M, Zylstra JL, Allum WH, Langley RE, Tan P, Valeri N, Sadanandam A. A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. Ann Oncol 2018; 29: 2356-2362 [PMID: 30481267 DOI: 10.1093/annonc/mdy407]

Maeda O, Ando T, Ohmiya N, Ishiguro K, Watanabe O, Miyahara R, Hibi Y, Nagai T, Yamada K, Goto H. Alteration of gene expression and DNA methylation in drug-resistant gastric cancer. Oncol Rep 2014; 31: 1883-1890 [PMID: 24904010 DOI: 10.3892/or.2014.3041]
